Copenhagen, Denmark, July 9, 2014 / B3C newswire / - Nuevolution is pleased to announce that Professor Paul Workman has joined as Scientific Advisor. Paul brings a vast knowledge and expertise within the oncology field to Nuevolution as well as profound understanding of bridging research discoveries with commercial value.
Professor Workman is an exceptionally experienced research leader, having achieved a high level of success in academia, biotech companies and the pharmaceutical industry. He is a Biochemist and Cancer Pharmacologist by training and he has worked at a number of academic institutions including Cambridge University, UK, Stanford University, California and the University of Glasgow, UK before moving to AstraZeneca, Alderley Park, UK as Head of the Cancer Bioscience Section in 1993. In 1997, Paul joined The Institute of Cancer Research (ICR), London to build the Cancer Research UK Cancer Therapeutics Unit (CTU) and also co-founded two successful biotech companies, Piramed Pharma and Chroma Therapeutics. As well as being the Director of the ICR’s CTU and Harrap Professor of Pharmacology and Therapeutics, Paul was recently appointed Interim Chief Executive of ICR, having been Deputy CEO for the last 3 years. Paul has received many scientific achievement awards including the American Association of Cancer Research Team Science Award (Team Leader) in 2012 and Cancer Research UK Translational Cancer Research Prize (Joint Leader of HSP90 Team) in 2013. In addition, he has received both the Sosnovsky Award in Cancer Therapy (2010) and the World Entrepreneur of the Year Award (2012) from the Royal Society of Chemistry and earlier this year received the international Raymond Bourgine Award for excellence in cancer research.
“We are happy to further expand our collaboration with Paul and to have him join our expert advisory panel. Paul and his team at ICR have had a truly remarkable success rate and an outstanding track record in bringing compounds to the clinic” said Thomas Franch, CSO of Nuevolution. “We are certain that Paul’s expertise will help accelerate our oncology projects further to meet our ambitions of providing novel compounds for cancer treatment”
Professor Workman said: “I am delighted to join Nuevolution’s advisors and am impressed by their proprietary Chemetics® technologies that provide an unprecedented capability for the identification of drug leads and a strong potential to address major unmet medical needs”.
Nuevolution is dedicated to the identification and progression of novel compounds addressing unmet medical needs with a main disease focus on Inflammation and Oncology. The company currently has efforts on more than 30 disease targets at various discovery stages in its pipeline or in collaboration with several industrial, institutional and academic partners.
Nuevolution is a leading small molecule lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics®, a unique, patent protected hybrid of proven wet chemistry and molecular biology, which represents the ultimate fragment, based drug discovery technology. Chemetics® enables rapid oligonucleotide e.g. DNA encoded synthesis of up to billions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented speed and scale.
Nuevolution partners its technology with pharmaceutical and biotechnology companies, and has entered into drug discovery agreements with Merck, Novartis, Boehringer Ingelheim, Cancer Research Technology and The Institute of Cancer Research. Furthermore, Lexicon Pharmaceuticals, GlaxoSmithKline and Novartis have entered technology licensing agreements with Nuevolution. Nuevolution participates in a scientific joint venture consortium (Nuevolution, Duke University, Howard Hughes Medical Institute, Lexicon Pharmaceuticals) focusing on GPCR’s, and Nuevolution is currently in the optimization phase for compounds identified under a joint venture consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and BRIC focusing on epigenetics. Nuevolution has demonstrated the power of Chemetics® by identification of highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation and oncology. Nuevolution is a privately owned company by key Scandinavian investors, including SEB Venture Capital, Sunstone Capital, Industrifonden, SLS Invest, Novo Ventures and Innoventus Life Sciences.
Chemetics® is a registered trademark of Nuevolution.
Chemetics® is a patented technology of Nuevolution: EP1402024, US7,727,713, EP1487978, US7,413,854, EP1756277, EP1608748, US 7,915,201, EP1558744, AU2003273792, CN-ZL20038010476, HKHK1082742, IN213390, IL167531, JP4895608, ZA2005/02624, NZ538993, SG111515, US8,206,901, US7,704,925, EP1957644,EP07114663.3, EP10184311.8, US12/330,709, EP08169346.7, US12/179,323, EP03766117.0, US10/523,006, US10/539,288, US13/179,283, EP09154197.9, AU2011226815, CA2,544,153, CN201210222023.8, EP10183942.1, EP10184069.2, HK11107861.8, HK11107866.3, IL207672, IL207673, IN178/MUMNP/2007, JP2010-226107, JP2013-155967, US11/402,957, US13/455,223, US10/572,644, EP10192716.8, EP10192717.6, US12/095,778, EP09765460.2, US12/999,267, EP11720372.9, IN9924/DELNP/2012, US13/641,588.
Thomas Franch, CSO
Phone: +45 7020 0987